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Abstract. 31 
Background. A 1 mg/L susceptibility breakpoint for ceftaroline and staphylococci is 32 
universally agreed; EUCAST counts MIC >1 mg/L as resistant; CLSI and FDA count 2 33 
mg/L as intermediate and >2 mg/L resistant.  We investigated whether routine 34 
diagnostic tests reliably distinguish MICs of 1 versus 2 mg/L.  Methods.  Thirty-five UK 35 
laboratories collected Staphylococcus aureus isolates and performed tests with 5 g 36 
(as EUCAST) or 30 g (as CLSI) discs and either confluent growth on Mueller-Hinton 37 
agar (as EUCAST and CLSI) or semi-confluent growth on IsoSensitest agar (as 38 
BSAC). They also ran Etests for MRSA. Reference MICs were determined centrally by 39 
CLSI and BSAC agar dilution.  Results. 1607 S. aureus (33% MRSA) had paired local 40 
disc and central MIC results. EUCAST’s zone breakpoint recognised 56% of isolates 41 
found resistant in MIC tests, but the positive predictive value (PPV) for resistance was 42 
11.0%; corresponding proportions by CLSI testing were 28.0% and 13.4%. The BSAC 43 
disc method detected 25% of resistant isolates, with a PPV of 18.2%. Agreement, +1 44 
dilution, of local Etests and central agar MICs was >95%, but only 20% of the isolates 45 
found non-susceptible by agar dilution were found non-susceptible by Etest, and vice-46 
versa. Review for isolates with the modal MIC (0.25 mg/L) indicated that the same 47 
laboratories reported large or small zones irrespective of disc and method, implying 48 
systematic bias.  Conclusion. MRSA with ceftaroline MICs of 1 and 2 mg/L were 49 
poorly discriminated by routine methods.  Solutions lie in greater standardisation, 50 
automation, or dosages justifying a higher breakpoint. 51 
52 
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Introduction 53 
Ceftaroline is a recently-licensed cephalosporin that binds and inactivates PBP2’ 54 
(PBP2a), which determines meticillin resistance in staphylococci.1  Phase III trials in 55 
skin and skin structure infection (SSSI) indicated non-inferiority to vancomycin and 56 
equivalent efficacy against meticillin-resistant and -susceptible Staphylococcus aureus 57 
(MRSA and MSSA).2  Case reports suggest anti-MRSA efficacy in various off-label 58 
settings, where use deserved more formal investigation, including diabetic foot 59 
infections3  and endocarditis.4 60 
 MICs for most MRSA are 0.25-1 mg/L, compared with 0.12-0.25 mg/L for 61 
MSSA.1   MICs of 2 mg/L are found for c. 5% of MRSA in most trials and surveys5-7 62 
though for 19.4% of isolates in one study in the Far East.8 MICs exceeding 2 mg/L are 63 
extremely rare, but values of 4 mg/L were found for four MRSA from Greece. These 64 
had diverse mutations to PBP2’,9 as did isolates with MICs 2-4 mg/L from Germany.10  65 
A cystic fibrosis isolate with an MIC >32 mg/L also had a modified PBP2’.11 EUCAST 66 
has set breakpoints of S <1 mg/L, R >1 mg/L,12 whereas the US Food and Drug 67 
Administration (FDA) and CLSI both have values of S <1, I=2 and R >2.  EUCAST, 68 
CLSI and BSAC have set zone breakpoints corresponding to these values,12-15 but it 69 
is uncertain whether diagnostic laboratories can reliably distinguish the minorities of 70 
isolates with reduced susceptibility under ‘real-life’ conditions.10 To test this, we 71 
recruited a panel of UK laboratories to test consecutive S. aureus isolates by disc and 72 
Etest methods and to refer the results, along with the isolates themselves, which then 73 
had MICs determined centrally.  Results of the local and central testing were 74 
compared.  75 
 76 
Materials and methods 77 
SSSI survey 78 
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The SSSI survey, in which isolates were collected, has been described elsewhere.16  79 
Briefly we recruited 40 UK diagnostic microbiology laboratories, and asked each to 80 
collect 60 consecutive clinically-significant SSSI isolates from hospitalised patients, 81 
also a subsequent 15 MRSA from SSSIs. Collection ran from August 2012 to 82 
December 2013 and 35 of the 40 laboratories contributed isolates (See 83 
Acknowledgements): 29 sites were in England, three in Scotland, two in Wales and 84 
one in Northern Ireland.  S. aureus dominated the collection, and is the only species 85 
considered here. 86 
 87 
Local susceptibility testing  88 
The laboratories were asked to perform susceptibility tests with 5 and 30 g discs on 89 
their S. aureus isolates following: (i) British Society for Antimicrobial Chemotherapy 90 
(BSAC) methodology with semi-confluent growth and IsoSensitest agar,17 and (ii) 91 
EUCAST/CLSI protocols with Mueller-Hinton agar and confluent growth.18  The 5 and 92 
30 g discs were from Oxoid-Thermofisher, Basingstoke, UK and Mast Diagnostics, 93 
Merseyside, UK, respectively; they were from single batches and were supplied 94 
centrally.  Laboratories were also asked to determine ceftaroline MICs for their MRSA 95 
(not MSSA) isolates using Etests (bioMerieux, Basingstoke, UK, again from a single 96 
batch), following the manufacturer’s protocol, with Mueller-Hinton agar and confluent 97 
growth.  98 
  Except for discs and Etests, all other materials, including agars and diluents 99 
were sourced locally by the laboratories, as in routine practice. All sites held UK Clinical 100 
Pathology Accreditation. 101 
 102 
Central laboratory testing 103 
Isolates collected by the participating laboratories were also sent to the Antimicrobial 104 
Resistance and Healthcare Associated Infections Reference Unit (AMRHAI) where 105 
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they were confirmed as S. aureus with Chromagar Staph aureus (Chromagar, Paris, 106 
France), with PCR to seek mecA.19 MICs of ceftaroline (AstraZeneca, Macclesfield, 107 
UK) were determined by BSAC agar dilution20 on IsoSensitest agar (Oxoid-108 
Thermofisher, Basingstoke, UK) and by CLSI agar dilution21 on Mueller Hinton agar 109 
(Oxoid).    110 
 111 
Results  112 
Paired local disc tests and central MIC results were obtained for 1076 MSSA and for 113 
531 MRSA, with local Etest results available for 525 of the MRSA.  These totals differ 114 
minimally from the SSSI survey report,16 owing to inclusion of a few isolates received 115 
as ‘supplementary MRSA’ that proved to be MSSA on reference laboratory testing. 116 
Numbers of S. aureus per site ranged from six to 47, with a mean of 28. 117 
 118 
Agreement within central susceptibility testing at AMRHAI 119 
MIC tests by the two agar dilution methods were run in parallel at AMRHAI. With 11 120 
(0.7%) exceptions among the 1607 isolates, MICs by CLSI agar dilution equalled those 121 
by BSAC agar dilution or were two-fold higher (Table 1).  MICs of 2 mg/L were found 122 
for 25 MRSA isolates by CLSI methodology (considered intermediate) and for eight of 123 
these (and no others) by BSAC methodology (considered resistant).  No MICs 124 
exceeded 2 mg/L by either method (i.e. none of the isolates were considered resistant 125 
by CLSI criteria). 126 
 127 
Agreement of local disc and central MIC testing 128 
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A relationship existed between the zones found locally and the MICs found centrally, 129 
such that mean zone diameters reduced as MICs rose (Table 2). Nevertheless 130 
correlation coefficients for zone versus log MIC were unimpressive, at 0.56 and 0.47 131 
for 5 and 30 g discs, respectively, on IsoSensitest agar with semi-confluent growth 132 
and 0.63 and 0.54, respectively for the same discs on Mueller-Hinton agar with 133 
confluent growth. Irrespective of the combination of method and disc type, there was 134 
considerable overlap of the zone sizes for isolates with MICs of 2 mg/L and those for 135 
isolates with lower MICs.  136 
 137 
Disc-based categorisation with EUCAST and CLSI criteria 138 
EUCAST specifies interpretive criteria of R <20 mm, S >20 mm using a 5 g ceftaroline 139 
disc on Mueller-Hinton agar with confluent growth. This recognised as resistant only 140 
14/25 (56%) isolates with MICs >1 mg/L (by the CLSI method; Table 2, panel 1). 141 
However 113 susceptible isolates were mis-categorised as resistant, giving a false 142 
resistance rate of 7.1% and leading to a ‘resistant’ result having a positive predictive 143 
value (PPV) of just 11.0%. CLSI has interpretive criteria of R <20 mm; I, 21-23 mm 144 
and S >24 mm for a 30 g disc, again on Mueller-Hinton agar with confluent growth. 145 
No isolates counted as resistant using CLSI’s MIC criteria (>2 mg/L) and, among the 146 
25 that scored as intermediate (MIC 2 mg/L) the disc method correctly recognised only 147 
seven (28%; Table 2, panel 2). Five fully-susceptible isolates gave zones of <20 mm, 148 
equating to a false resistance (major error) rate of 0.3%, and 40 gave zones of 21-23 149 
mm. The PPV of a non-susceptible zone result was 13.4%.  150 
 The BSAC did not have zone breakpoints for ceftaroline at the time of this 151 
study, but has since published values of R <19 mm, S >20 mm for 5 g discs, which 152 
are slightly more liberal those of EUCAST, despite the less rich medium and lighter 153 
inoculum. These values correctly categorised only two of the eight isolates with MICs 154 
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of 2 mg/L as resistant (25%); nine susceptible isolates (0.5%) were mis-classified as 155 
resistant and the PPV of a resistant result was 18.2%. A breakpoint of R <23 mm 156 
correctly discriminated all eight isolates with MICs of 2 mg/L, but led to 207/1599 157 
susceptible isolates being mis-categorised as resistant, meaning that the false 158 
resistance rate rose to 12.9% with a PPV for a resistant result of only 3.7%.  159 
Discrimination with 30 g discs was even poorer.  160 
 161 
Agreement of local Etest to central MIC tests 162 
After rounding to match the normal doubling dilution scale, 500/525 (95.3%) of locally-163 
determined Etest MICs were in essential agreement (i.e. +1 doubling dilution) with the 164 
values found centrally by CLSI agar dilution, taken as a reference (Table 3).  165 
Nevertheless, discrimination between MICs of 1 and 2 mg/L remained poor:  Among 166 
the 25 isolates with MICs of 2 mg/L by CLSI agar dilution, just five (20%) were found 167 
non-susceptible by Etest, with MICs of 1.5-2 mg/L.  Counterwise, among 24 isolates 168 
with MICs of 1.5-4 mg/L by Etest, just five were found non-susceptible by agar dilution 169 
MICs.  These data indicate 20% sensitivity for detection of MIC 2 mg/L, a false 170 
resistance/non-susceptibility rate of 4% and a PPV, for a ‘non-susceptible’ result 171 
predicting true resistance of 20%. 172 
 173 
Differences in zone results among sites 174 
The generally poor agreement between local and central results led us to consider 175 
cross-method agreement within sites. We reviewed laboratories’ zone data for all 176 
isolates where the central laboratory had found an MIC of 0.25 mg/L. This was the 177 
modal MIC by each method, found for 967 isolates by the BSAC method and 1011 by 178 
the CLSI technique; it remained the modal MIC for all batches of isolates tested 179 
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centrally, indicating testing consistency. We then calculated, for each laboratory and 180 
test type, the mean zone diameters for isolates with this MIC (Table 4).   181 
The mean zones for these isolates on Mueller-Hinton agar varied among 182 
laboratories  by 7.4 mm with 30 g discs and 6.5 mm with 5 g discs.  Corresponding 183 
variations on IsoSensitest agar were 5.8 and 4.6 mm, respectively. There was 184 
extremely strong correlation between the mean zones found for the two disc contents 185 
within each method (r= 0.93 within Mueller-Hinton/confluent growth and 0.91 within 186 
IsoSensitest/semi-confluent) and weaker correlation between results for the same disc 187 
type between the two different methods (r= 0.61 for 30 g discs and 0.62 for 5 g 188 
discs). These relationships are unsurprising because, within each method, the two 189 
discs would ordinarily be tested on the same plate with the same depth and inoculum, 190 
whereas the media and inocula differ between the methods. Nevertheless correlation 191 
coefficients of 0.61-0.62 suggest a relationship, and inspection shows that the 192 
laboratories which found the largest and smallest zone diameters for one combination 193 
of method and disc did so also for other combinations (Table 4). 194 
 195 
Discussion 196 
The FDA, EUCAST and CLSI all agree a susceptible breakpoint of 1 mg/L for 197 
ceftaroline, based on the licensed 600 mg every 12 hours regimen, pharmacodynamic 198 
analysis and Monte Carlo simulation.14  This breakpoint divides around 5% of UK 199 
MRSA as resistant; the proportion may be higher or lower elsewhere according to 200 
locally prevalent strains, though MICs >2 mg/L seem to be rare everywhere.  Unlike 201 
EUCAST, CLSI and FDA categorise MICs of 2 mg/L as intermediate.  Rationales for 202 
the intermediate category have not been published: some pharmacodynamic analyses 203 
do support a 2 mg/L breakpoint based on the 600 mg every 12 hours regimen;22 204 
alternatively CLSI (unlike EUCAST) sometimes includes an intermediate category as 205 
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a buffer zone to minimise “major” and “very major” errors. In Phase III SSSI clinical 206 
trials ceftaroline achieved cures in 142/152 MRSA cases,2 but the proportion of isolates 207 
with MICs of 2 mg/L was tiny.  The present study sought to establish whether 208 
diagnostic laboratories could reliably use these breakpoints -and corresponding zone 209 
values- to distinguish isolates with MICs of 1 versus 2 mg/L. 210 
We found that, in routine use, none of the combinations of disc and method 211 
achieved a satisfactory balance of sensitivity and PPV for resistance detection.  212 
EUCAST’s <20 mm breakpoint with 5 g discs detected 56% of resistant (on EUCAST 213 
criteria) isolates, but at the price of categorising many susceptible isolates as resistant, 214 
so that the PPV for a resistant zone result was only 11.0%.   CLSI’s 215 
susceptible/intermediate breakpoint of 23 mm for 30 g discs recognised just 28% of 216 
the isolates with MICs 2 mg/L as non-susceptible, with a PPV of 13.4%.  A breakpoint 217 
(this study) of 23 mm for the BSAC method with 5 g discs recognised all resistant 218 
isolates, but had a derisory PPV of 3.7%; the BSAC’s subsequently-published R <19 219 
mm16 value detected only two of eight resistant isolates, with a PPV of 18.2%.  Zone 220 
breakpoints could be adjusted to improve detection sensitivity for resistance or to 221 
increase the PPV, but these two criteria are counterpoised, meaning that any change 222 
to improve one will worsen the other.    Gradient strips are widely advocated when disc 223 
tests are unreliable but, although essential agreement to agar dilution MICs was 224 
excellent at 95%, minor disagreements again meant that the detection sensitivity for 225 
isolates with an MIC of 2 mg/L was only 20%, with a PPV of 20%.  Like others11 we 226 
found that MICs by Etest were commonly one doubling dilution below those by dilution 227 
methodology. 228 
 The present analysis is disappointing compared with EUCAST’s published 229 
study,12 which found 92% categorical agreement between ceftaroline disc and MIC 230 
tests for MRSA. The likely explanation is that the EUCAST study included a tight quality 231 
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control specifically for ceftaroline whereas we took the view that laboratories had 232 
general quality control for susceptibility testing and wished to assess likely variability 233 
in real-life conditions.   234 
To further investigate inter-site variation we reviewed zones for all isolates 235 
where the central laboratory found an MIC of 0.25 mg/L and, irrespective of disc and 236 
method, found substantial variation in different laboratories’ mean zones for these 237 
‘homogeneous’ isolates. Variation was greater by CLSI/EUCAST methodology than by 238 
BSAC (Table 4) perhaps because standardisation to the BSAC method was more 239 
familiar to UK laboratories, or because it is inherently easier, with a single manufacturer 240 
of the base medium (IsoSensitest agar) and with semi-confluent growth that can easily 241 
be judged as adequate or not by eye. Strikingly, the same laboratories obtained the 242 
largest and smallest zones irrespective of the disc content or method.  This implies 243 
that differences in inocula, agar depth or how zones are read, are the major arbiter of 244 
variation, not variation in media or disc quality (which was a source of recent comment 245 
and concern23). 246 
 Three solutions might be proposed. First, disc testing and reading might be 247 
made more precise. Secondly, automated systems –which do not depend on the 248 
human eye to judge a zone edge or the end of growth on a gradient strip– might replace 249 
disc testing. Thirdly, ceftaroline might be dosed at levels to justify a higher breakpoint. 250 
EUCAST stresses that zones for control strains should fall in the middle of the 251 
published quality control ranges and that laboratories consistently obtaining results at 252 
the extremes of ranges or >1 mm either side of the expected value, should review their 253 
performance;24 the International Standards Organisation is also taking an interest in 254 
the improved standardisation of disc testing.  Both these organisations can do much 255 
to encourage improved quality, precision and reproducibility of disc testing, 256 
nevertheless zone scatter of +3 mm per doubling dilution between tests and 257 
laboratories is not uncommon, meaning that MICs of 1 and 2 mg/L seem certain ot 258 
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remain hard to discriminate by diffusion testing.  With regard to dosage, a trial of 259 
ceftaroline at 600 every 8 hours instead of every 12 hours has recently been completed 260 
in bacteraemic SSSI (Clinical Trials Identifier NCT01499277 https://clinicaltrials.gov) 261 
and may justify a 2 mg/L breakpoint. 262 
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Table 1.  Agreement of MICs by BSAC and CLSI methods, as found centrally  
 MIC by BSAC method Total 
MSSA 
Total 
MRSA 
Grand 
total MIC by CLSI method 0.015 0.03 0.06 0.125 0.25 0.5 1 2 
0.06 1 1 5      7  7 
0.125   2 41 2    45  45 
0.25   1 95 909 6   1004 7 1011 
0.5     56 126 1  20 163 183 
1      195 141   336 336 
2       17 8  25 25 
Total MSSA 1 1 8 135 919 12      
Total MRSA    1 48 315 159 8    
Grand Total 1 1 8 136 967 327 159 8 1076 531 1607 
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Table 2.  Agreement between locally determined inhibition zones (mm) and centrally determined MICs for ceftaroline 
Panel 1. Mueller-Hinton agar, confluent growth 5 g disc, as EUCAST (shaded: zones resistant on EUCAST criteria) versus MICs by CLSI agar dilution 
MIC, 
mg/L 
6 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 
3
4 
35 >36 
Mean 
zone 
+SD 
2  2   1 1 6 1 3 4 2 1    1 1 2         19.4+4.3 
1  2 1 3 2 4 6 31 43 70 65 42 27 9 14 8 4 2 1 1 1      20.8+2.6 
0.5  1   1 1  4 7 22 34 35 20 14 21 8 6 3  5 1      22.6+2.8 
0.25 2       1 3 5 20 64 87 122 142 131 117 91 81 67 35 18 12 6 3 4 26.2+3.1 
0.125            1   1 5 5 7 9 5 4 4 3 1   29.0+2.5 
0.06         1       1 1  2   2     27.7+4.5 
Total 2 5 1 3 4 6 12 37 57 101 121 143 134 145 178 154 134 105 93 78 41 24 15 7 3 4  
 
Panel 2: Mueller-Hinton agar, confluent growth 30 g disc as CLSI (dark grey, resistant by CLSI zone criteria; light grey, intermediate) versus MICs by CLSI 
agar dilution 
MIC, 
mg/L 
6 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 >42 
Mean 
zone 
+SD 
2    2 1 4 1 5 4 3 1 1 3             25.5+2.6 
1  1 2 5 6 11 34 68 69 49 42 16 19 11 2 1          26.3+2.4 
0.5   1 2 5 9 14 17 24 28 25 19 20 10 3 2 2 1  1      27.2+2.8 
0.25 1    3 4 8 23 52 78 123 114 145 109 106 69 67 49 27 19 7 2 2  3 30.4+3.2 
0.125            3 5 2 9 5 5 10 3  2 1    33.2+2.5 
0.06       1     1   2 1    2      32.0+4.5 
 Total 1 1 3 9 15 28 58 113 149 158 191 154 192 132 122 78 74 60 30 22 9 3 2  3  
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Panel 3: IsoSensitest, semi-confluent growth, 5 g disc (shaded: zones resistant on BSAC criteria16 ) versus MICs by BSAC agar dilution 
MIC, 
mg/L 
6 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 >37 
Mean 
zone +SD 
2    1 1   3 2 1               20.6+2.1 
1    1 2 1 5 15 23 24 26 32 14 9 5 1 1        23.7+2.2 
0.5 1  1   1 5 15 34 45 61 67 42 32 16 3 2 1 1      24.4+2.3 
0.25        1 9 22 55 151 133 126 128 72 101 69 36 25 21 9 6 3 27.8+2.9 
0.125 1 1         3 2 4 8 11 11 28 15 17 16 10 5 4  30.3+3.6 
0.06           2  1 1   2 1     1  28.5+4.1 
0.03                        1  
0.015                         1  
 Total 2 1 1 2 3 2 10 34 68 92 147 252 194 176 160 87 134 86 54 41 31 14 11 5  
 
Panel 4: IsoSensitest, semi-confluent growth, 30 g disc versus MICs by BSAC agar dilution 
MIC 
(mg/L) 
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 >42 
Mean 
zone 
+SD 
2          1 2 2 2 1             28.0+1.3 
1    1 1 1 2 1 5 7 15 28 19 32 19 17 6 4   1      29.2+.2.6 
0.5 1    2  4 3 8 16 20 37 59 79 31 32 21 7 3 3  1     29.6+2.6 
0.25      1   7 7 23 42 81 165 119 133 81 85 78 51 43 22 10 13 1 5 32.2+3.1 
0.125           3 1 1 4 5 19 11 14 21 17 14 8 7 6 2 3 34.9+3.2 
0.06             1 1 2  1 1 1     1   32.9+3.5 
0.03                         1   
0.015                          1  
 Total 1   1 3 2 6 4 20 31 63 110 163 282 176 201 120 111 103 71 58 31 17 20 4 9  
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Table 3.  Local Etest results versus central MIC result on Mueller-Hinton agar for MRSA isolates (n=531)  
 
Count of isolates with indicated MIC (mg/L) by Etest  
MIC (mg/L) 
by CLSI agar dilution 0.125 0.19 0.25 0.38 0.5 0.75 1 1.5 2 3 4 
Grand 
Total 
2    1 4 4 11 3 2   25 
1   8 45 95 122 50 8 1 1 3 333 
0.5 1 4 15 56 51 26 1  2 2 2 160 
0.25   3 2 1 1      7 
Grand Total 1 4 26 103 151 153 62 11 5 3 5 525 
 
Shaded results are in essential agreement, after routing Etest values to the normal doubling dilution scale 
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Table 4. Mean zones, as found at participating laboratories for isolates with ceftaroline MICs of 0.25 mg/L found centrally 
Lab  
No isolates 
with MIC 
0.25 mg/L 
found 
centrally 
by CLSI 
method 
CLSI/EUCAST method 
No isolates with 
MIC 0.25 mg/L 
centrally by 
BSAC method 
BSAC Method 
30-g disc 5-g disc 30-g disc 5-g disc 
Mean zone 
(mm) 
SD (mm) 
Mean zone 
(mm) 
SD 
(mm) 
Mean zone 
(mm) 
SD (mm) 
Mean 
zone 
(mm) 
SD (mm) 
CC 35 27.1 2.5 24 2.3 34 30.1 2.6 26.2 2.5 
CH 33 27.9 2.4 24 2.9 33 31.1 2.2 27.0 2.1 
CZ 32 28.3 2.3 23.8 2.3 35 32.9 3.5 27.5 3.1 
DJ 32 29 2.2 26 2.1 31 31.2 2.8 28.0 2.7 
DK 19 29.2 2.6 24.9 2.6 19 34.1 2.6 29.6 2.8 
DM 25 29.2 2.7 25.2 2.9 26 31.7 4.8 26.5 3.8 
CW 34 29.5 2.0 24.9 2 35 32.1 2.5 27.2 2.7 
DB 43 29.5 2.1 25.2 2.4 35 29.1 2.7 25.3 2.2 
CF 21 29.7 2.1 25.6 2.3 22 32.1 2.2 27.5 2.4 
CJ 28 29.8 2.5 24.6 2.3 26 31.4 2.2 26.2 1.9 
CK 22 29.8 2.4 26.1 2.3 20 32.0 2.7 27.5 2.2 
CM 41 29.8 2.5 26.2 2.7 37 32.1 2.7 27.6 2.5 
CP 29 29.8 2.9 25.8 2.7 27 32.7 4.0 28.6 3.5 
CG 23 29.9 2.8 25.7 2.3 22 31.3 3.2 27.3 3.1 
DC 32 29.9 2.9 25.3 2.7 30 31.6 3.1 27.2 3.1 
CX 21 30.3 3.1 25.8 2.9 19 30.9 2.9 26.0 2.4 
DI 28 30.3 2.5 25.9 2.6 26 32.4 1.9 28.2 1.8 
DL 36 30.3 2.4 26.4 2.4 27 32 2.7 28.5 2.7 
CO 37 30.4 2.9 26.6 2.6 38 31.6 3.3 27.7 3.3 
DF 16 30.4 3.6 26.3 3.5 15 34.1 3.6 29.3 3.4 
CE 31 30.6 2.4 26.8 2.6 31 33.6 3 29.3 2.8 
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CQ 35 30.9 3.4 26.4 3 35 32.3 2.9 28.3 2.8 
CT 34 30.9 3.0 26.8 3.2 31 31.4 2.2 27.4 2.6 
DD 37 31.1 3.3 26.4 3.3 39 32.5 2.9 27.1 2.5 
CS 11 31.2 2.8 25.1 6.7 12 32.1 1.8 27.7 2.1 
CI 37 31.5 6.4 27.3 5.8 38 32.5 2.9 27.9 2.6 
CL 18 31.5 2.1 27.2 2 19 34.2 1.9 29.3 2 
CN 39 31.5 3.1 26.2 3 39 33.7 3 28.8 2.8 
CR 20 31.7 2.6 27 2.1 20 32.2 2.8 27.6 2.1 
DO 6 31.7 1.5 27.7 2.7 6 32.7 2.7 27.7 2.9 
CB 48 31.8 2.8 27.1 2 47 32.2 3.1 27.9 2.6 
CV 32 32.4 2.8 27.8 2.5 28 32.6 3 28.3 3 
CY 35 33.3 2.8 29 2.6 33 34.1 3.3 29.6 3.2 
CU 20 33.7 2.1 29.3 2 13 34.9 3.1 29.9 2.8 
DH 21 34.5 2.7 30.3 2.8 19 34.1 3 29.5 2.7 
 
The five lowest values are shaded grey and the five highest shown as white type on a black background; more than five values are highlighted in the event of 
‘ties’. 
 
 
